

Resource Summary Report

Generated by [nidm-terms](#) on Aug 11, 2026

Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488

RRID:AB_2534080

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# A-11013, RRID:AB_2534080)

Antibody Information

URL: http://antibodyregistry.org/AB_2534080

Proper Citation: (Thermo Fisher Scientific Cat# A-11013, RRID:AB_2534080)

Target Antigen: Human IgG (H+L)

Host Organism: goat

Clonality: polyclonal secondary

Comments: Applications: Flow, ICC/IF

Antibody Name: Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488

Description: This polyclonal secondary targets Human IgG (H+L)

Target Organism: human

Defining Citation: [PMID:12145302](#), [PMID:18230399](#), [PMID:17092910](#), [PMID:16862147](#), [PMID:11081627](#), [PMID:17035329](#), [PMID:16906129](#), [PMID:12237301](#), [PMID:11248215](#), [PMID:14678267](#), [PMID:18077360](#), [PMID:12356868](#), [PMID:16129882](#), [PMID:16484228](#)

Antibody ID: AB_2534080

Vendor: Thermo Fisher Scientific

Catalog Number: A-11013

Record Creation Time: 20251213T073340+0000

Record Last Update: 20260225T230501+0000

Ratings and Alerts

No rating or validation information has been found for Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488.

No alerts have been found for Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 488.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 63 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Ning W, et al. (2026) A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. Cell reports. Medicine, 7(4), 102688.

Oka N, et al. (2026) Donepezil ameliorates fatigue and depression in PASC patients with HHV-6B SITH-1-induced acetylcholine deficiency. Frontiers in pharmacology, 17, 1807203.

Bhavsar D, et al. (2026) Structural and functional characterization of the antigenicity of influenza A virus hemagglutinin subtype H15. Cell reports, 45(1), 116773.

Ren X, et al. (2026) Humanization and engineering of protective antibodies targeting severe fever with thrombocytopenia syndrome virus Gn protein. Cell reports, 45(2), 116936.

Zhang J, et al. (2026) Characterization of white adipocyte heterogeneity using data-driven microscopy. International journal of obesity (2005).

Acciani M, et al. (2026) Human neutralizing antibodies targeting the measles virus hemagglutinin and fusion surface proteins. Cell host & microbe, 34(6), 1067.

Wang M, et al. (2026) Impaired VLCFA-peroxisome-mediated intestinal epithelial repair causes gastrointestinal sequelae of long COVID. Developmental cell.

Liu J, et al. (2026) Targeting the noncanonical function of metabolic enzyme PHGDH in driving PD-L1 expression and cancer immune evasion. Cell reports. Medicine, 7(4), 102704.

Wang Q, et al. (2026) A practical alternative to live cell-based assay for AQP4 and MOG antibody detection. EBioMedicine, 129, 106338.

Maher SP, et al. (2025) A drug repurposing approach reveals targetable epigenetic pathways in *Plasmodium vivax* hypnozoites. *eLife*, 13.

Wang S, et al. (2025) NKG2D receptor ligands are cell surface biomarkers for injured murine and human nociceptive sensory neurons. *Journal of neuroinflammation*, 23(1), 42.

Hegelmaier T, et al. (2025) Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis. *Med (New York, N.Y.)*, 6(9), 100776.

Singh G, et al. (2025) Characterization of the glycoproteins of fish and amphibian influenza B-like viruses. *Science advances*, 11(34), eady8610.

Wang W, et al. (2025) Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potency. *Cell chemical biology*, 32(8), 1042.

Liang R, et al. (2025) Epistasis in the receptor-binding domain of contemporary H3N2 viruses that reverted to bind sialylated di-LacNAc repeats. *Cell reports*, 44(8), 116007.

Lindland K, et al. (2025) Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. *Molecular cancer therapeutics*, 24(9), 1415.

Morizane A, et al. (2025) Control of immune response in an iPSC-based allogeneic cell therapy clinical trial for Parkinson's disease. *Cell stem cell*, 32(9), 1346.

Li W, et al. (2025) Structure and function of a pair of non-competing monoclonal antibodies against Langya henipavirus attachment glycoprotein. *Cell reports*, 44(10), 116407.

Xu J, et al. (2025) Bispecific targeting of 4-1BB and CCR8 boosts antitumor immunity via Ti-Treg depletion and CD8⁺ activation. *iScience*, 28(7), 112829.

Ma CB, et al. (2025) Multiple independent acquisitions of ACE2 usage in MERS-related coronaviruses. *Cell*, 188(6), 1693.